Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hanke
Susan Hanke, Toulouse FR
| Patent application number | Description | Published |
|---|---|---|
| 20090070091 | METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR THE OPTIMIZATION OF POWER SYSTEM ARCHITECTURES AT THE AIRCRAFT LEVEL DURING PRE-DESIGN - In an aircraft power system architecture, power requirements stem from functional top-level aircraft requirements and from the interrelationship among many systems. Thus, to balance power in the overall aircraft power system architecture or at least a portion of the power system architecture at the aircraft level, these interrelationships are considered. A method, system and computer program product are provided for the management of power system architectures at the aircraft level during pre-design. The designer can specify top-level aircraft parameters, and power values in all the systems of the aircraft at varying levels of complexity can be displayed. | 03-12-2009 |
Tomas Hanke, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20080306244 | Renta: an HIV immunogen and uses thereof - The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, including Reverse Trancriptase (RT), Env (gp41), Nef and Tat proteins, as well as at least one HIV CTL epitope associated with long-term, non-progression to AIDS; these domains are biologically-inactivated for one or more of the normal activity of those proteins or are partial protein sequences (and similarly biologically-inactivated). RENTA is an AFP in which the HIV domains are from an HIV Clade A consensus sequence and contains additional domains, useful for example, in monitoring expression levels or laboratory animal immune responses. Such domains are optionally included in the AFPs. Other aspects of the invention may include compositions for and methods of inducing an anti-HIV immune response in a subject, preferably using a DNA prime-MVA boost strategy, and preferably to induce a cell-mediated immune response. | 12-11-2008 |
| 20100266635 | HIVCON: AN HIV IMMUNOGEN AND USES THEREOF - The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV Glade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response. | 10-21-2010 |
| 20110159034 | METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSE - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 06-30-2011 |
Tomas Hanke, Old Marston GB
| Patent application number | Description | Published |
|---|---|---|
| 20090191237 | Methods and reagents for vaccination which generate A CD8 T cell immune response - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 07-30-2009 |
| 20090324632 | Methods and reagents for vaccination which generate a CD8 T cell immune response - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 12-31-2009 |
| 20100119551 | Methods and reagents for vaccination which generate a CD8 T cell immune response - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 05-13-2010 |